INTRODUCTION {#s1}
============

Wilms tumor (WT) is the most common childhood renal malignancy.^[@B1]^ Most patients are treated effectively, with approximately 90% achieving 5-year survival, but new approaches are needed to improve the outcome of the remainder, especially in cases of recurrence, where only approximately 50% will survive.^[@B2],[@B3]^ More specific biomarkers for treatment stratification could also reduce the therapeutic burden on the successfully treated majority. Treatment planning is currently determined by clinical staging and histopathologic criteria. In countries that follow the protocols of the International Society of Paediatric Oncology (SIOP), patients with WT typically receive neoadjuvant chemotherapy, and the histopathology at nephrectomy is used to classify patients into risk groups. Tumors with diffuse anaplasia or that contain a high proportion of chemoresistant blastema (blastemal type) are regarded as high risk; epithelial, stromal, mixed, and regressive subtypes are classed as intermediate risk, and completely necrotic tumors are classed as low risk.^[@B4]^ Using this classification, the SIOP WT 2001 trial recently reported that doxorubicin can be safely omitted from the treatment of stage II to III intermediate-risk histology tumors, although it still adds benefit when patients have high-risk histology.^[@B5],[@B6]^ However, high-risk tumors are relatively uncommon, and most relapses still occur in patients with localized (stage I to III) low- and intermediate-risk histology tumors. Therefore, there is a clinical need to improve the sensitivity and specificity of risk prediction in WT. The SIOP WT 2001 trial included, as a secondary aim, investigation of the potential value of including molecular biomarkers in addition to the current use of tumor stage and histology in risk stratification.

Previous analyses have identified multiple recurrent aberrations in WT. Notable genes with documented mutations include *WT1*,^[@B7]-[@B9]^ *CTNNB1*,^[@B10]^ *WTX* (*AMER1*),^[@B11]^ *TP53*,^[@B12]^ *FBXW7*,^[@B13]^ *MYCN*, *SIX1/2*, *DICER1*, *DROSHA*, and *DGCR8*.^[@B14]-[@B18]^ Copy neutral loss of heterozygosity on 11p, common in stromal-type tumors, can lead to both second hit inactivation of mutated *WT1* on 11p13 and aberrant expression of the imprinted genes *H19* and *IGF2* on 11p15; the latter locus is also frequently targeted by epigenetic abnormalities.^[@B19]^ Several WT genes, including *WT1*, *WTX*, *TP53*, *FBXW7*, and *MYCN* are also subject to recurrent copy number aberrations, as are a number of larger-scale genomic regions, but few of these are of known prognostic relevance. Simultaneous allele loss of 1p and 16q is associated with adverse outcome in patients with favorable-histology WT treated with immediate nephrectomy, and this biomarker is already used in treatment stratification by the Children\'s Oncology Group of North America.^[@B20]^ We have recently shown that *TP53* mutation and 17p loss, aberrations largely confined to anaplastic histology WT, are potential adverse indicators within this subtype.^[@B21]^ However, the utility of both these biomarkers is limited by their relative rarity. Genomic gain of 1q, one of the most common copy number changes in WT,^[@B22]-[@B25]^ seems to be associated with poor outcome, as is gain of *MYCN*.^[@B18]^ Recent studies in the United States and United Kingdom have focused on the significance of 1q gain and support its prognostic value.^[@B26],[@B27]^

The principal aim of this study was to assess the feasibility of using 1q gain as a prognostic biomarker by determining its association with event-free survival (EFS) and overall survival (OS) in a cohort drawn entirely from the SIOP WT 2001 clinical trial (which is, to our knowledge, the largest SIOP cohort so far analyzed for this biomarker). Accordingly, a rapid and relatively low-cost multiplex ligation-dependent probe amplification (MLPA) assay^[@B28]^ was developed and optimized to assess the copy number status of 1q and other key regions or gene-specific loci, including 1p, 16q, *WT1*, *WTX*, *TP53*, *MYCN,* and *FBXW7*.

MATERIALS AND METHODS {#s2}
=====================

Patients {#s3}
--------

Patients registered prospectively in the SIOP WT 2001 clinical trial and treated with preoperative chemotherapy according to standardized risk-stratified regimens on the basis of tumor stage, histology, and metastatic response to preoperative chemotherapy^[@B5],[@B29]^ with stage I to IV WT and available frozen tumor were eligible for this study. Selection criteria and patient characteristics are provided in the Data Supplement (Methods). Informed consent was obtained from all families. Our research was approved by local ethics committees and conducted in accordance with the Helsinki Declaration.

Samples {#s4}
-------

All samples were freshly frozen specimens obtained at nephrectomy. Genomic DNA was prepared by standard methods. Only WT with a tumor content ≥ 50% as determined by a pediatric pathologist were used for this study (N = 586; Data Supplement Table S1). Full details, including sample inclusion criteria and DNA quality control (QC) metrics, are listed in the Data Supplement.

MLPA {#s5}
----

The MLPA assay (P380-X2) was designed and developed in collaboration with MRC-Holland (Amsterdam, the Netherlands). The panel included 33 probes for regions or genes of interest, including seven on 1p, five on 1q, six on 16q, and three each targeting *MYCN* (2p), *TP53* (17p), *FBXW7* (4q), *WT1* (11p), and *WTX* (*AMER1*, Xq), as well as reference and QC probes (Data Supplement Table S2). MLPA reactions were performed according to the manufacturer's instructions, with appropriate internal quality and external normal controls. Polymerase chain reaction products were analyzed on an ABI 3730 DNA Analyzer, (Thermo Fisher Scientific, Waltham, MA).

Data Analysis {#s6}
-------------

Copy number ratios relative to the normal reference were calculated with Coffalyser.NET software (MRC-Holland) using the default settings. A numerical gain was scored when the ratios exceeded 1.2 and a loss when the ratios were lower than 0.8; all other values were considered to be normal diploid. For individual genes, aberrations were scored by the median ratio of the gene-specific probes. For 1p, 1q, and 16q, a gain or loss of at least two consecutive probed loci was required to score a chromosome arm aberration. Associations between copy number aberrations and histopathologic subtypes ([Fig 1](#F1){ref-type="fig"}) were calculated by logistic regression, and survival analyses ([Table 1](#T1){ref-type="table"}; [Fig 2](#F2){ref-type="fig"}; Data Supplement) were performed using the Kaplan-Meier estimator, log-rank test, and Cox proportional hazards regression model (Data Supplement Methods). For multivariable analyses, the factors considered are listed in the "Variable" column of [Table 2](#T2){ref-type="table"}.

![Aberration frequency histograms for loci of interest in specific histologic subtypes of Wilms tumor (full series, N = 586). AH, anaplastic histology.](jco660001f1){#F1}

![(A, C, E) Event-free (EFS) and (B, D, F) overall survival (OS) curves for (A, B) complete series, (C, D) intermediate-risk localized disease, and (E, F) nonanaplastic localized disease Wilms tumors, stratified by 1q status. AH, anaplastic histology.](jco660001f2){#F2}

###### 

Univariable Survival Analyses

![](jco660001t1)

  Patient Series        Aberration   No. of Patients   No. of Relapses   Event *P*   Event HR   5-Year EFS   No. of Deaths   Death *P*   Death HR   5-Year OS
  --------------------- ------------ ----------------- ----------------- ----------- ---------- ------------ --------------- ----------- ---------- -----------
  Unselected patients   1q gain      167               43                \< .001     2.33       75           19              .01         2.16       88.4
  (N = 586)             1q other     419               49                88.2        22         94.4                                                
  1p loss               49           11                .17               1.55        77.9       5            .38             1.52        89         
  1p other              537          81                85                36          93                                                             
  16q loss              94           20                .12               1.48        78.5       11           .07             1.88        89.1       
  16q other             492          72                85.5              30          93.3                                                           
  1p and 16q loss       16           3                 .76               1.22        81.2       0            .27             0.01        100        
  1p and 16q other      570          89                84.5              41          92.4                                                           
  *TP53* (17p) loss     44           19                \< .001           4.03        55.2       16           \< .001         9.80        63.7       
  *TP53* (17p) other    542          73                86.7              25          94.9                                                           
  *WT1* (11p) loss      50           6                 .45               0.73        86.6       1            .15             0.26        97.8       
  *WT1* (11p) other     536          86                84.2              40          92.2                                                           
  *WTX* (Xq) loss       93           10                .13               0.61        91.4       2            .04             0.26        97.8       
  *WTX* (Xq) other      493          82                83                39          91.6                                                           
  *MYCN* (2p) gain      88           26                \< .001           2.45        71.2       14           \< .001         3.09        83.7       
  *MYCN* (2p) other     498          66                86.7              27          94.2                                                           
  *MYCN* (only) gain    60           20                \< .001           2.72        67.9       12           \< .001         3.91        79.4       
  *MYCN* (only) other   526          72                86.3              29          94.2                                                           
  *FBXW7* (4q) loss     24           15                \< .001           6.58        38         10           \< .001         9.62        59.3       
  *FBXW7* (4q) other    562          77                86.4              31          94                                                             
  IR stage I-III        1q gain      114               22                .004        2.21       82.2         3               .99         1.01       98
  (n = 441)             1q other     327               29                91.3        8          97.3                                                
  1p loss               34           6                 .27               1.61        83.7       1            .88             1.17        97         
  1p other              407          45                89.4              10          97.5                                                           
  16q loss              59           9                 .4                1.36        84.6       3            .21             2.27        96.4       
  16q other             382          42                89.5              8           97.6                                                           
  1p and 16q loss       13           2                 .69               1.33        84.6       0            .56             0.01        100        
  1p and 16q other      428          49                89                11          97.4                                                           
  *TP53* (17p) loss     19           6                 .004              3.23        67.4       3            \< .001         8.33        88.2       
  *TP53* (17p) other    422          45                89.9              8           97.8                                                           
  *WT1* (11p) loss      42           5                 .94               1.03        86.3       0            .29             0.00        100        
  *WT1* (11p) other     399          46                89.2              11          97.2                                                           
  *WTX* (Xq) loss       79           8                 .58               0.81        92.4       0            .11             0.00        100        
  *WTX* (Xq) other      362          43                88.1              11          96.9                                                           
  *MYCN* (2p) gain      61           14                .003              2.49        78.2       4            .03             3.50        93.4       
  *MYCN* (2p) other     380          37                90.7              7           98.1                                                           
  *MYCN* (only) gain    42           11                .001              2.86        75.7       4            .002            5.49        90.3       
  *MYCN* (only) other   399          40                90.3              7           98.2                                                           
  *FBXW7* (4q) loss     13           6                 \< .001           4.85        59.3       1            .23             3.25        100        
  *FBXW7* (4q) other    428          45                89.9              10          97.4                                                           
  Non-AH stage I-III    1q gain      131               26                .001        2.34       81.4         6               .1          2.48       95.7
  (n = 482)             1q other     351               30                91.4        6          98.1                                                
  1p loss               42           8                 .13               1.78        82         3            .05             3.47        92.3       
  1p other              440          48                89.3              9           97.9                                                           
  16q loss              64           9                 .59               1.22        85.7       2            .8              1.22        98.4       
  16q other             418          47                89                10          97.2                                                           
  1p and 16q loss       14           2                 .76               1.25        85.7       0            .55             0.01        100        
  1p and 16q other      468          54                88.7              12          97.3                                                           
  *TP53* (17p) loss     17           5                 .02               2.82        69.3       2            .02             5.24        93.3       
  *TP53* (17p) other    465          51                89.3              10          97.5                                                           
  *WT1* (11p) loss      45           5                 .9                0.94        87.4       0            .27             0.00        100        
  *WT1* (11p) other     437          51                88.7              12          97.1                                                           
  *WTX* (Xq) loss       81           8                 .5                0.77        92.6       0            .1              0.00        100        
  *WTX* (Xq) other      401          48                87.7              12          96.8                                                           
  *MYCN* (2p) gain      63           14                .01               2.30        78.9       4            .04             3.23        93.4       
  *MYCN* (2p) other     419          42                90.1              8           98                                                             
  *MYCN* (only) gain    43           11                .002              2.68        76.2       4            .003            5.10        90.3       
  *MYCN* (only) other   439          45                89.8              8           98.1                                                           
  *FBXW7* (4q) loss     13           6                 \< .001           4.83        59.3       1            .23             3.28        100        
  *FBXW7* (4q) other    469          50                89.5              11          97.3                                                           

Abbreviations: AH, anaplastic histology; EFS, event-free survival; HR, hazard ratio; IR, intermediate risk; OS, overall survival.

###### 

Multivariable Survival Analyses

![](jco660001t2)

  Patient Series                  Variable            Comparison   Event-Free Survival   Overall Survival                                           
  ------------------------------- ------------------- ------------ --------------------- ------------------ ------ --------- ------- ------ ------- ------
  Unselected patients (n = 585)   1p loss             No loss      .95                   0.98               0.5    1.91      .45     0.67   0.24    1.89
  1q gain                         No gain             .002         1.98                  1.27               3.07   .16       1.61    0.83   3.15    
  16q loss                        No loss             .63          1.14                  0.68               1.91   .39       1.37    0.67   2.83    
  Female                          Male                .98          0.99                  0.65               1.51   .81       0.93    0.49   1.74    
  Stage II                        Stage I             .43          1.27                  0.71               2.27   .06       3.13    0.96   10.26   
  Stage III                       Stage I             .17          1.52                  0.83               2.79   .01       4.39    1.36   14.12   
  Stage IV                        Stage I             \< .001      4.58                  2.58               8.15   \< .001   21.65   6.93   67.66   
  High risk                       Intermediate risk   .001         2.28                  1.41               3.68   \< .001   8.13    4.05   16.32   
  Age                             Per unit            .06          1.01                  1                  1.01   .48       1       0.99   1.01    
  IR stage I-III (n = 440)        1p loss             No loss      .97                   1.02               0.41   2.5       .84     0.81   0.1     6.74
  1q gain                         No gain             .04          1.92                  1.05               3.51   .44       0.56    0.13   2.42    
  16q loss                        No loss             .64          1.2                   0.56               2.55   .09       3.51    0.82   15.12   
  Female                          Male                .27          0.73                  0.41               1.28   .04       0.24    0.06   0.92    
  Stage II                        Stage I             .76          1.11                  0.57               2.18   .13       3.25    0.71   14.82   
  Stage III                       Stage I             .13          1.73                  0.85               3.54   .02       7.01    1.45   33.78   
  Age                             Per unit            .32          1                     1                  1.01   .71       1       0.99   1.02    
  Non-AH stage I-III (n = 481)    1p loss             No loss      .73                   1.15               0.52   2.54      .45     1.75   0.4     7.61
  1q gain                         No gain             .02          2                     1.13               3.57   .62       1.39    0.38   5.11    
  16q loss                        No loss             .96          0.98                  0.46               2.06   .77       1.27    0.26   6.29    
  Female                          Male                .33          0.77                  0.45               1.31   .04       0.24    0.06   0.93    
  Stage II                        Stage I             .36          1.34                  0.72               2.5    .05       5.12    0.99   26.4    
  Stage III                       Stage I             .26          1.51                  0.74               3.08   .06       5.58    0.91   34.08   
  High risk                       Intermediate risk   .71          0.85                  0.38               1.94   .45       1.71    0.42   7       
  Age                             Per unit            .11          1.01                  1                  1.01   .53       1.01    0.99   1.02    

Abbreviations: AH, anaplastic histology; HR, hazard ratio; IR, intermediate risk.

RESULTS {#s7}
=======

Sample Series and Histologic Subtypes {#s8}
-------------------------------------

A total of 586 patients with stages I to IV WTs, in which tumor content was confirmed by histologic review, high-quality DNA was successfully extracted, and data exceeded QC thresholds (Data Supplement Methods), were included in the analysis. In this series (Data Supplement Table S1), median clinical follow-up was 68 months, 92 patients had an event (relapse), and 41 patients died. In 55% of tumors (321 of 586), at least one of the major copy number aberrations targeted by the assay (1q gain, 1p loss, 16q loss, *MYCN* gain, *TP53* loss, *WT1* loss, *WTX* loss, or *FBXW7* loss) was detected (Data Supplement Table S1). Overall, the numbers of alterations identified across all markers were consistent with previous reports. Some aberrations were more common in specific subtypes ([Fig 1](#F1){ref-type="fig"}; Data Supplement Table S3) and some significant associations were noted. Compared with mixed-type histology, diffuse anaplasia was significantly associated with *TP53* (17p) loss (*P* \< .001), *MYCN* (2p) gain (*P* \< .001), 16q loss (*P* \< .001), and *FBXW7* (4q) loss (*P* \< .001), the latter presumably reflecting an association between anaplasia and whole-arm 4q loss, which we have described previously.^[@B30]^ The stromal subtype was associated with *WT1* (11p) loss (*P* = .0014), consistent with previous reports, and with a significantly lower frequency of 1q gain than the other subtypes (*P* = .00912). A gain of 1q was most frequent in blastemal-type tumors ([Fig 1](#F1){ref-type="fig"}), but not to a statistically significant extent. We also noted an association between the regressive type and a lower frequency of *WTX* (*AMER1*, Xq) loss. Most aberrations, including 1q gain, were somewhat less common in stage I than in higher stage tumors (Data Supplement Table S4).

Univariable Outcome Analysis of 1q Gain {#s9}
---------------------------------------

In the complete series of 586 patients ([Table 1](#T1){ref-type="table"}; [Figs 2A and 2B](#F2){ref-type="fig"}), 167 tumors (28.5%) had 1q gain. Five-year EFS in the 1q-gain group was 75.0% (95% CI, 68.5% to 82.0%) and 88.2% in the no-gain group (95% CI, 85.0% to 91.4%). The corresponding OS values were 88.4% (95% CI, 83.5% to 93.6%) and 94.4% (95% CI, 92.1% to 96.7%), respectively. At the alpha significance level of .05, univariable analyses using the Cox proportional hazards regression model showed that 1q gain was associated with poorer EFS (hazard ratio \[HR\], 2.33; log-rank *P* \< .001) and OS (HR, 2.16; *P* = .01).

Because 1q gain as a potential biomarker would be of most value in optimizing risk stratification in localized tumors, we also considered two important subsets. The first consisted of 441 patients with localized disease (stage I to III), intermediate-risk histology tumors according to the SIOP classification. In univariable analysis ([Table 1](#T1){ref-type="table"}; [Figs 2C and 2D](#F2){ref-type="fig"}), 1q gain was significantly associated with inferior EFS (*P* = .004; HR, 2.21) but not OS (*P* = .99; HR, 1.01). The second subset was selected to allow direct comparison with the Children's Oncology Group risk stratification. Among 482 patients with localized, nonanaplastic tumors (ie, excluding both diffuse and focal anaplastic but including blastemal-type WTs), 1q gain was associated with poorer EFS (*P* = .001; HR, 2.34) but not OS (*P* = .1; HR, 2.48; [Table 1](#T1){ref-type="table"}; [Figs 2E and 2F](#F2){ref-type="fig"}).

Univariable Outcome Analysis of 1p Loss and 16q Loss {#s10}
----------------------------------------------------

Neither 1p loss nor 16q loss, nor combined loss of 1p and 16q, considered as a single biomarker in a univariable Cox model, was significantly associated with EFS or OS in the entire tumor series at the *P* = .05 level (Data Supplement). This was also true for the subsets, with the single exception of a marginal association between 1p loss and poorer OS in nonanaplastic patients ([Table 1](#T1){ref-type="table"}; Data Supplement Figs S1, S2, and S3).

Multivariable Outcome Analyses {#s11}
------------------------------

In a multivariable outcome analysis including 1q gain, 1p loss, 16q loss, tumor stage and histologic risk group, sex, and age, 1q gain was significantly associated with poorer EFS (HR, 1.98; *P* = .002), but not OS (HR, 1.61; *P* = .16; [Table 2](#T2){ref-type="table"}). The only other independent factors of those assessed for adverse outcome in the full series (N = 586) were high-risk histology and stage IV disease. The significant independent association of 1q gain with adverse EFS but not OS persisted in the subsets of intermediate-risk histology, localized WT (n = 440; EFS HR, 1.92; *P* = .04) and nonanaplastic, localized WT (n = 481; EFS HR, 2.0; *P* = .02).

Univariable Analysis of Gene-Specific Markers {#s12}
---------------------------------------------

The outcome data for the other markers covered by the assay were also analyzed on an exploratory basis ([Table 1](#T1){ref-type="table"}; Data Supplement Figs S4-S9). *MYCN* (2p) gain was significantly associated with poorer EFS and OS in the complete data set, in the localized disease intermediate-risk subset, and in the localized disease subset with anaplastic WTs excluded (Data Supplement Fig S4). Using a more specific definition of *MYCN* gain, *MYCN*-only gain (excluding from the *MYCN*-gain group those tumors in which the *DYSF* control probe on 2p was also gained, because gains at both loci were likely to be whole-arm gains), we saw higher HRs and lower *P* values ([Table 1](#T1){ref-type="table"}; Data Supplement Fig S5). Similarly, *TP53* (17p) loss was significantly associated with inferior EFS and OS in the complete series and, perhaps surprisingly, in both subsets, neither of which included diffuse anaplastic WTs ([Table 1](#T1){ref-type="table"}; Data Supplement Fig S6).

A third copy number change, loss of the *FBXW7* locus on 4q, was significantly associated with poorer EFS and OS in the complete 586 tumor series, but only with poorer EFS in both subsets ([Table 1](#T1){ref-type="table"}; Data Supplement Fig S7). No significant associations were noted between the copy number status of *WT1* and outcome at the *P* = .05 significance level ([Table 1](#T1){ref-type="table"}; Data Supplement Fig S8). For *WTX*, there was no significant association with EFS, but improved OS was marginally associated with copy number loss in the complete series only (*P* = .04; Data Supplement Fig S9).

DISCUSSION {#s13}
==========

This is, to our knowledge, the first study to carry out a large-scale analysis of 1q copy number aberrations in WT sampled at nephrectomy after neoadjuvant chemotherapy according to the SIOP WT 2001 protocol. The clinical characteristics of the patient cohort were representative of the entire registered population who had received preoperative chemotherapy and presented with unilateral disease; 586 patients with stage I to IV WT, including all intermediate- and high-risk histologic subtypes, were analyzed. We found that 1q gain is significantly associated with poorer EFS and OS in univariable analyses, with HRs in excess of two-fold for relapse and death. These results are broadly consistent with those recently reported in a study of patients treated by immediate nephrectomy under Children\'s Oncology Group protocols without preoperative chemotherapy^[@B26]^ and, although it is essential to assess 1q gain independently in cohorts treated under both regimens, it is encouraging to note that it seems to be a prognostically valuable marker regardless of treatment protocol. However, in our multivariable analysis of the SIOP data, which also considered 1p loss, 16q loss, sex, stage, age, and histologic risk group, 1q gain remained significantly associated only with EFS (HR, 1.98; *P* = .002) and not OS (HR, 1.61; *P* = .16). This lack of association with OS is perhaps not surprising, given the comparatively low number of deaths in the patient series (41, compared with 92 relapses), reflecting the relative success of second-line therapy.

Because just over half of all relapses occur in children with localized WT that are not of high-risk histology, we analyzed this subset of patients (n = 441) in which treatment intensification to reduce relapse risk would be clinically appropriate and feasible. Here, we found that 1q gain retained its independent prognostic significance for EFS (HR, 1.92; *P* = .04) but not OS in multivariable analysis. Similar results (HR, 2.00; *P* = .02) were obtained for localized nonanaplastic tumors (n = 481), excluding both diffuse and focal anaplastic WTs but retaining blastemal type. This subset is comparable to the current North American definition of favorable histology for localized patients treated by immediate nephrectomy (where blastemal type, which implies chemoresistance, cannot be defined).

In contrast to a previous report on immediate nephrectomy patients,^[@B20]^ we did not find that the combination of 1p loss and 16q loss was prognostically significant in the SIOP series in the univariable or multivariable analyses. This was true for both EFS and OS, in the entire series, and in the nonanaplastic and intermediate-risk subsets. However, the size of our sample series (significantly smaller than the immediate nephrectomy cohort) meant that the current study did not have sufficient power to assess reliably the prognostic significance of relatively rare aberrations such as combined 1p and 16q loss, observed in only 16 patients (three of whom relapsed). We note also that any copy neutral loss of heterozygosity, another possible mechanism of allele loss at these loci, would not be detected by MLPA. A substantially larger series would be required to obtain definitive results for this rare combined marker in SIOP patients.

In a previous study,^[@B18]^ we presented an analysis of *MYCN* copy number status that included 234 of the samples described in this study. Therefore, our observations are not independent, but the current expanded series should give a more reliable indication of the prognostic relevance of *MYCN* gain. As before, we note that *MYCN* gain seems to be a promising adverse prognostic indicator for WT, for both EFS and OS (Data Supplement Fig S4). We also analyzed the data using a more specific definition of gain (*MYCN*-only gain; Data Supplement Fig S5), excluding whole-arm gains. The adverse association with both EFS and OS was retained in all univariable analyses, but with lower *P* values and higher HRs throughout, perhaps suggesting that the type of genomic disruption that has given rise to *MYCN* gain, rather than the relative dose of *MYCN* with regard to the genomic baseline, is more prognostically relevant. A higher resolution (eg, single nucleotide polymorphism array) platform that allows precise delineation of the region of gain and distinguishes between focal events, such as those we described previously,^[@B13]^ and larger segmental changes would allow us to address this question.

In a previous study we described an association between poor outcome and *TP53* aberrations (typically point mutation coincident with whole-arm copy number loss of 17p) in diffuse anaplastic tumors.^[@B21]^ Interestingly, *TP53* (17p) loss in the current study was associated with poorer EFS and OS, even in the subsets that excluded anaplastic tumors. It is currently not known whether the nonanaplastic tumors with copy number loss at this locus also had *TP53* mutations or whether these tumors had any unusual histologic features, such as nuclear unrest.^[@B31]^

Loss of the *FBXW7* locus on 4q was significantly associated with poorer EFS and OS in the complete tumor series and with adverse EFS only in the subsets. In earlier studies, we reported focal homozygous loss and point mutation of *FBXW7* in several intermediate-risk histology WTs,^[@B13]^ as well as broader but typically single copy loss of 4q associated with anaplasia^[@B30]^; the current assay does not distinguish between these types of aberrations.

Optimizing treatment to minimize the risk of long-term adverse effects without compromising EFS or OS is a principal aim of clinical research in WT. The previous SIOP randomized trial^[@B5],[@B6]^ showed that therapeutic intensity could be reduced in patients with localized intermediate-risk tumors without affecting OS, at the cost of a 4.4% reduction in EFS (95% CI, 0.4% to 9.3%). Because it is clearly desirable for patients to avoid even treatable relapses, further refinement of first-line therapy remains a priority, and novel biomarkers may provide the key data required to improve risk stratification and maximize EFS. In this study, we have shown that MLPA provides a rapid and effective means of determining the status of copy number aberrations associated with poorer EFS. The relatively high frequency of 1q gain makes this marker particularly attractive for potential use in risk stratification. However, any change in intensity on the basis of 1q status alone would affect a significant proportion of patients who have experienced a reasonably good EFS when treated with current therapies and where relapse is salvageable. Hence, the SIOP Renal Tumours Study Group considers it may be more appropriate to define risk groups for treatment stratification on the basis of several combined molecular biomarkers, taking account of our findings of the adverse significance of *MYCN* gain and *TP53* loss and incorporating mutations in recently discovered WT genes, some of which are reported to have prognostic significance. This requires a prospective clinical study powered to include tumor stage and histologic risk group, both individually significant in our multivariable analysis, alongside quantitative assessment of the volume of blastema that survives preoperative chemotherapy, a further potential prognostic factor.^[@B32]^ This prospective study will also incorporate multiple sampling of each WT to determine the extent of intratumoral heterogeneity of 1q gain and other biomarkers. It will register all patients with a newly diagnosed renal tumor and continue the risk stratification and treatment arms for localized WT used in the SIOP WT 2001 trial. The study will be known as UMBRELLA, and is expected to open in 2016.
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